» Articles » PMID: 38890304

Expression and Functional Implications of YME1L in Nasopharyngeal Carcinoma

Overview
Journal Cell Death Dis
Date 2024 Jun 18
PMID 38890304
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondria play a crucial role in the progression of nasopharyngeal carcinoma (NPC). YME1L, a member of the AAA ATPase family, is a key regulator of mitochondrial function and has been implicated in various cellular processes and diseases. This study investigates the expression and functional significance of YME1L in NPC. YME1L exhibits significant upregulation in NPC tissues from patients and across various primary human NPC cells, while its expression remains relatively low in adjacent normal tissues and primary nasal epithelial cells. Employing genetic silencing through the shRNA strategy or knockout (KO) via the CRISPR-sgRNA method, we demonstrated that YME1L depletion disrupted mitochondrial function, leading to mitochondrial depolarization, reactive oxygen species (ROS) generation, lipid peroxidation, and ATP reduction within primary NPC cells. Additionally, YME1L silencing or KO substantially impeded cell viability, proliferation, cell cycle progression, and migratory capabilities, concomitant with an augmentation of Caspase-apoptosis activation in primary NPC cells. Conversely, ectopic YME1L expression conferred pro-tumorigenic attributes, enhancing ATP production and bolstering NPC cell proliferation and migration. Moreover, our findings illuminate the pivotal role of YME1L in Akt-mTOR activation within NPC cells, with Akt-S6K phosphorylation exhibiting a significant decline upon YME1L depletion but enhancement upon YME1L overexpression. In YME1L-silenced primary NPC cells, the introduction of a constitutively-active Akt1 mutant (caAkt1, at S473D) restored Akt-S6K phosphorylation, effectively ameliorating the inhibitory effects imposed by YME1L shRNA. In vivo studies revealed that intratumoral administration of YME1L-shRNA-expressing adeno-associated virus (AAV) curtailed subcutaneous NPC xenograft growth in nude mice. Furthermore, YME1L downregulation, concurrent with mitochondrial dysfunction and ATP reduction, oxidative injury, Akt-mTOR inactivation, and apoptosis induction were evident within YME1L-silenced NPC xenograft tissues. Collectively, these findings shed light on the notable pro-tumorigenic role by overexpressed YME1L in NPC, with a plausible mechanism involving the promotion of Akt-mTOR activation.

Citing Articles

DIA/SWATH-Mass Spectrometry Revealing Melanoma Cell Proteome Transformations with Silver Nanoparticles: An Innovative Comparative Study.

Martano S, Faktor J, Kote S, Cascione M, Di Corato R, Faktorova D Int J Mol Sci. 2025; 26(5).

PMID: 40076651 PMC: 11901134. DOI: 10.3390/ijms26052029.


Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth.

Zhao Y, Wu S, Cao G, Song P, Lan C, Zhang L Cell Death Dis. 2025; 16(1):95.

PMID: 39948081 PMC: 11825924. DOI: 10.1038/s41419-025-07419-0.


Targeting POLRMT by IMT1 inhibits colorectal cancer cell growth.

Wang H, Liu Y, Lu X, Wu Y, Gu W, Yin G Cell Death Dis. 2024; 15(9):643.

PMID: 39227564 PMC: 11372113. DOI: 10.1038/s41419-024-07023-8.

References
1.
Prawira A, Oosting S, Chen T, Delos Santos K, Saluja R, Wang L . Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. Br J Cancer. 2017; 117(12):1743-1752. PMC: 5729473. DOI: 10.1038/bjc.2017.357. View

2.
MacVicar T, Ohba Y, Nolte H, Mayer F, Tatsuta T, Sprenger H . Lipid signalling drives proteolytic rewiring of mitochondria by YME1L. Nature. 2019; 575(7782):361-365. DOI: 10.1038/s41586-019-1738-6. View

3.
Xia Y, He C, Hu Z, Wu Z, Hui Y, Liu Y . The mitochondrial protein YME1 Like 1 is important for non-small cell lung cancer cell growth. Int J Biol Sci. 2023; 19(6):1778-1790. PMC: 10092760. DOI: 10.7150/ijbs.82217. View

4.
Liu J, Zhan X, Li M, Li G, Zhang P, Xiao Z . Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. BMC Med Genomics. 2012; 5:62. PMC: 3539862. DOI: 10.1186/1755-8794-5-62. View

5.
Guo Y, Chen G, Huang M, Wang Y, Liu Y, Jiang Q . TIMM44 is a potential therapeutic target of human glioma. Theranostics. 2022; 12(17):7586-7602. PMC: 9691352. DOI: 10.7150/thno.78616. View